Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2002

View Archived Issues

Oncogene expression linked to instability of ribonucleotide reductase R2 gene

Inhibition of stromelysin 1 holds promise in the management of abdominal aortic aneurysm

Patients with lipodystrophy successfully treated with leptin replacement

Inhale announces multiple collaborations

Kinetek validates PKB/Akt inhibitors as proapoptotic compounds

Rhodacyanine dyes synthesized with potent and selective antimalarial activity

Tipranavir plus ritonavir: pharmacokinetics in healthy volunteers reported in Seattle

Atazanavir does not adversely affect and may have beneficial effects on lipid profiles

Local delivery of L-arginine reduces in-stent neointimal hyperplasia in humans

Specific COX-2 inhibitors as a class do not appear to adversely affect cardiovascular system

Aventis Pasteur reports that HVTN 501 trial will not proceed

Troponin I suppresses growth of lung metastases in mice

Genta updates R&D progress in 2001

Indena's Sabalselect to be evaluated in benign prostatic hyperplasia trial

BVT-933 achieves proof of concept in phase IIa obesity trial

NeuroVax achieves primary endpoint in phase I/II trial in MS

NicOx summarizes R&D progress in 2001

Lactam MMP inhibitors claimed by DuPont (now BMS)

Heterocyclic carboxamides from Pharmacia inhibit human cytomegalovirus polymerase

Cell adhesion inhibitors as antiinflammatory and immunosuppressive agents

Selective chemokine CCR3 receptor antagonists described in patent by Novartis

New compounds modulate monoamine reuptake, claimed for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...